Skip to content
Home
Anaemia of CKD
Executive Summary
About this guideline
Introduction
Background
References
Summary of Clinical Practice Guidelines
Assessment for Anaemia of CKD (Guidelines 1.1 – 1.5)
Treatment of Anaemia of CKD with Iron (Guidelines 2.1 – 2.7)
Treatment of Anaemia with Erythropoiesis Stimulating Agents (Guidelines 3.1 – 3.17)
Treatment of Anaemia with HIF-PHI Agents (Guidelines 4.1 – 4.9)
Treatment of Anaemia of CKD with Blood Transfusions (Guidelines 5.1 – 5.1.3)
Management of Peri-Transplant and Post-Transplant Anaemia (Guidelines 6.1 – 6.3.3)
Special Populations (Guidelines 7.1 – 7.3)
Summary of Audit Measures on Anaemia of CKD
Summary of Research Recommendations
Rationale for Clinical Practice Guidance
New Therapies for Consideration in the Future
Lay Summary
Patient Information Leaflet for Anaemia of CKD
Authors
Guidelines
Anaemia of CKD Guideline
Blood Pressure
Haemodialysis
Hyperkalaemia
SGLT-2
Guidelines Library
Linkedin
Instagram
Youtube
Facebook
Home
Hyperkalaemia
1. Purpose of Guidelines Update
2. Summary of key changes to Hyperkalaemia Guideline: Hospital Section
3. Lay Summary
4. Guideline Development
5. Introduction
6. Summary of Clinical Practice Guideline for Hyperkalaemia
6.1. Section I Community
6.2. Section II Hospital
6.3. Section III Resuscitation
7. Tables
8. Figures
9. Summary of Audit Measures
10. Section I. Management of Hyperkalaemia in the Community and Outpatient Clinic
10.1.1. Monitoring patients (Guidelines 1.1 – 1.2)
10.1.2. RAASi Therapy: Assessment, Monitoring & Cessation (Guidelines 2.1 – 2.7)
10.1.3. Threshold for treating Hyperkalaemia (Guideline 3.1)
10.1.4. Indication for assessment in hospital (Guidelines 4.1-4.2)
10.1.5. Dietary intervention (Guidelines 5.1 – 5.2)
10.1.6. Sodium bicarbonate (Guideline 6.1)
10.1.7.Use of diuretics (Guideline 7.1)
10.1.8. Calcium resonium (Guideline 8.1)
10.1.9. Patiromer (Guidelines 9.1 – 9.3)
10.1.10. Sodium Zirconium Cyclosilicate (Guidelines 10.1 – 10.3)
10.1.11. Prevention of Hyperkalaemia (Guidelines 11.1 – 11.3)
Treatment Algorithm
11. Section II Management of Hyperkalaemia in Hospital
11.1.1. Clinical Assessment (Guideline 13.1)
11.1.2. ECG, Cardiac monitoring (Guidelines 14.1 – 14.2)
11.1.3. Laboratory tests (Guidelines 15.1 – 15.3)
11.1.4. Treatment strategy (Guidelines 16.1 – 16.6)
11.1.5. Blood monitoring (Guidelines 17.1 – 17.2)
11.1.6. Treatment in haemodialysis patients (Guidelines 18.1 – 18.4)
11.1.7. Referrals and treatment facilities (Guidelines 19.1 – 19.6)
11.1.8.Transfers (Guidelines 20.1 – 20.2)
11.1.9. Prevention (Guidelines 21.1 – 21.4)
11.1.10. Algorithm in Hospital (Guideline 22.1)
12. Section III. Management of Hyperkalaemia in Resuscitation
12.1.1.Cardiac arrest – special circumstance (Guideline 23.1)
12.1.2. Cardiac arrest – resuscitation and defibrillation ( Guidelines 24.1 – 24.2)
12.1.3. Cardiac arrest – treatments (Guidelines 25.1 – 25.4)
12.1.4. Prevention of cardiac arrest (Guidelines 26.1 – 26.2)
12.1.5. Algorithm in cardiac arrest (Guideline 27.1)
13. Algorithms
15.11. Appendix 6 ALGORITHM: Treatment of Hyperkalaemia in the Community
15.12. Appendix 7 ALGORITHM: Treatment of Hyperkalaemia in Hospital
15.13. Appendix 8 ALGORITHM: Treatment of Hyperkalaemia in Cardiac Arrest
14. Acknowledgements
15. Conflict of Interest
16. Appendices
15.1. Appendix 1 Efficacy of Insulin-Glucose in treatment of Hyperkalaemia15.1
15.2. Oral potassium lowering drugs
15.3. Appendix 3 Summary of Clinical Trials using oral potassium lowering drugs
15.4. Appendix 4A Drug administration and safety – IV CALCIUM PREPARATIONS
15.5. Appendix 4b Drug administration and safety – INSULIN-GLUCOSE INFUSION
15.6. Appendix 4c Drug administration and safety – SALBUTAMOL
15.7. Appendix 4d Drug administration and safety – PATIROMER
15.8. Appendix 4E Drug administration and safety – SODIUM ZIRCONIUM CYCLOSILICATE
15.9. Appendix 4F Drug administration and safety – CALCIUM RESONIUM
15.10. Appendix 5 Sine wave ECG
17. Abbreviatons
Authors
Guidelines
Anaemia of CKD
Blood Pressure
Haemodialysis
Hyperkalaemia
SGLT-2
Guidelines Library
Search Everything...
Navigate to sections
Home
Anaemia of CKD
Executive Summary
About this guideline
Introduction
Background
References
Summary of Clinical Practice Guidelines
Assessment for Anaemia of CKD (Guidelines 1.1 – 1.5)
Treatment of Anaemia of CKD with Iron (Guidelines 2.1 – 2.7)
Treatment of Anaemia with Erythropoiesis Stimulating Agents (Guidelines 3.1 – 3.17)
Treatment of Anaemia with HIF-PHI Agents (Guidelines 4.1 – 4.9)
Treatment of Anaemia of CKD with Blood Transfusions (Guidelines 5.1 – 5.1.3)
Management of Peri-Transplant and Post-Transplant Anaemia (Guidelines 6.1 – 6.3.3)
Special Populations (Guidelines 7.1 – 7.3)
Summary of Audit Measures on Anaemia of CKD
Summary of Research Recommendations
Rationale for Clinical Practice Guidance
New Therapies for Consideration in the Future
Lay Summary
Patient Information Leaflet for Anaemia of CKD
Authors
Guidelines
Anaemia of CKD Guideline
Blood Pressure
Haemodialysis
Hyperkalaemia
SGLT-2
Guidelines Library
1. Purpose of Guidelines Update
2. Summary of key changes to Hyperkalaemia Guideline: Hospital Section
3. Lay Summary
4. Guideline Development
5. Introduction
6. Summary of Clinical Practice Guideline for Hyperkalaemia
6.1. Section I Community
6.2. Section II Hospital
6.3. Section III Resuscitation
7. Tables
8. Figures
9. Summary of Audit Measures
10. Section I Management of Hyperkalaemia in the Community and Outpatient Clinic
10.1. I Hyperkalaemia in the Community (Guidelines 1 – 12)
10.1.1. Monitoring patients (Guidelines 1.1 – 1.2)
10.1.2. RAASi Therapy: Assessment, Monitoring & Cessation (Guidelines 2.1 – 2.7)
10.1.3. Threshold for treating Hyperkalaemia (Guideline 3.1)
10.1.4. Indication for assessment in hospital (Guidelines 4.1-4.2)
10.1.5. Dietary intervention (Guidelines 5.1 – 5.2)
10.1.6. Sodium bicarbonate (Guideline 6.1)
10.1.7. Use of diuretics (Guideline 7.1)
10.1.8. Calcium resonium (Guideline 8.1)
10.1.9. Patiromer (Guidelines 9.1 – 9.3)
10.1.10. Sodium Zirconium Cyclosilicate (Guidelines 10.1 – 10.3)
10.1.11. Prevention of Hyperkalaemia (Guidelines 11.1 – 11.3)
10.1.12. Treatment Algorithm (Guideline 12.1)
11. Section II Management of Hyperkalaemia in Hospital
11.1. II Hyperkalaemia in Hospital (Guidelines 13 – 22)
11.1.1. Clinical Assessment (Guideline 13.1)
11.1.2. ECG, Cardiac monitoring (Guidelines 14.1 – 14.2)
11.1.3. Laboratory tests (Guidelines 15.1 – 15.3)
11.1.4. Treatment strategy (Guidelines 16.1 – 16.6)
11.1.5. Blood monitoring (Guidelines 17.1 – 17.2)
11.1.6. Treatment in haemodialysis patients (Guidelines 18.1 – 18.4)
11.1.7. Referrals and treatment facilities (Guidelines 19.1 – 19.6)
11.1.8. Transfers (Guidelines 20.1 – 20.2)
11.1.9. Prevention (Guidelines 21.1 – 21.4)
11.1.10. Algorithm in Hospital (Guideline 22.1)
12. Section III Management of Hyperkalaemia in Resuscitation
12.1 Hyperkalaemia in Resuscitation (Guidelines 23 – 27)
12.1.1. Cardiac arrest – special circumstance (Guideline 23.1)
12.1.2. Cardiac arrest – resuscitation and defibrillation ( Guidelines 24.1 – 24.2)
12.1.3. Cardiac arrest – treatments (Guidelines 25.1 – 25.4)
12.1.4. Prevention of cardiac arrest (Guidelines 26.1 – 26.2)
12.1.5. Algorithm in cardiac arrest (Guideline 27.1)
13. Algorithms
15.11. Appendix 6. ALGORITHM: Treatment of Hyperkalaemia in the Community
15.12. Appendix 7. ALGORITHM: Treatment of Hyperkalaemia in Hospital
15.13. Appendix 8. ALGORITHM: Treatment of Hyperkalaemia in Cardiac Arrest
14. Acknowledgements
15. Conflict of Interest
15. Appendices
15.1. Appendix 1 Efficacy of Insulin-Glucose in treatment of Hyperkalaemia15.1
15.2. Oral potassium lowering drugs
15.3. Appendix 3. Summary of Clinical Trials using oral potassium lowering drugs
15.4. Appendix 4A. Drug administration and safety – IV CALCIUM PREPARATIONS
15.5. Appendix 4b. Drug administration and safety – INSULIN-GLUCOSE INFUSION
15.6. Appendix 4c. Drug administration and safety – SALBUTAMOL
15.7. Appendix 4d. Drug administration and safety – PATIROMER
15.8. Appendix 4E. Drug administration and safety – SODIUM ZIRCONIUM CYCLOSILICATE
15.9. Appendix 4F. Drug administration and safety – CALCIUM RESONIUM
15.10. Appendix 5. Sine wave ECG
16. Abbreviatons
Home
Hyperkalaemia
14. Conflict of Interest
14. Conflict of Interest
The authors have no conflict of interest.
